echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Kangfang Biology is rapidly advancing the phase II clinical study of IL-4Rα monoclonal antibody atopic dermatitis and asthma

    Kangfang Biology is rapidly advancing the phase II clinical study of IL-4Rα monoclonal antibody atopic dermatitis and asthma

    • Last Update: 2021-12-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hong Kong, October 15, 2021/PRNewswire/ - Recently, Kangfang Bio (9926.


    At the same time, the global phase II clinical trial of AK120 for the treatment of moderate to severe atopic dermatitis (AD) has completed the enrollment of the first patient in the first research center in the United States, and the research is progressing rapidly


    IL-4 and IL-13 are key drivers of type 2 inflammation


    In terms of safety, AK120 has completed a single-dose escalation phase Ia clinical study in healthy subjects and a multi-dose escalation phase Ib clinical study for the treatment of atopic dermatitis in New Zealand and Australia


    In terms of effectiveness, early clinical studies have shown that AK120 has a potential clinical efficacy comparable to or better than Dupliu in patients with atopic dermatitis


    Currently, China still lacks independent intellectual property rights for the treatment of moderate to severe asthma and moderate to severe atopic dermatitis biologics approved for marketing, and there is strong clinical demand


    IL-4Rα monoclonal antibody is considered to be an important target for the treatment of allergic diseases, and it is also one of the best-selling antibody protein drugs in the autoimmune field.


    About AK120

    AK120 is a new type of autoimmune disease treatment drug that targets IL-4Rα independently developed by Kangfang Biology.


    About Kangfang Bio

    Kangfang Bio (HKEx stock code: 9926.


    Source: Kangfang Bio

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.